In reply: Management of thin melanoma

In reply: Management of thin melanoma Dear Editor,In the letter entitled “Management of thin melanoma,” Drs. Pusiol and Piscioli outline an algorithm for classification of melanoma into one of three types; nontumorigenic microinvasive radial growth phase (RGP) thin melanoma, tumorigenic early vertical growth phase (VGP) thin melanoma, or uncertain potentially tumorigenic thin melanoma. Further, the authors suggest that treatment decisions regarding performance of sentinel lymph node biopsy (SLNB) be based on this classification alone, with the recommendation that SLNB be performed for any VGP thin melanoma with a potential for regional nodal metastasis.The decision to perform SLNB has historically been based on the probability of finding a positive sentinel lymph node using independent prognostic variables of tumor and patient characteristics. In our study of 510 patients with 512 melanoma lesions Breslow thickness 0.75‐0.99 mm, univariate analysis showed age ≤45, Breslow depth ≥0.85 mm, mitotic rate>1/mm2, and ulceration to be significantly associated with nodal disease (either positive SLNB or nodal recurrence in the follow up period). To our knowledge, RGP and VGP have not been shown to be independent prognostic indicators of risk of nodal metastasis and, although the risk is low, it has been shown that very early thin lesions and even those interpreted as melanoma in situ can metastasize.Given that SLNB is a surgical test with associated risks, the recommendation to perform SLNB has been and should continue to be based on the probability (percentage) and not the possibility (yes/no) of regional lymph node disease. As such, we feel strongly that the decision to perform SLNB should be based upon a reasonable evaluation of the likelihood of potential benefit appropriately weighed against the surgical risk.CONFLICTS OF INTERESTNone.Sincerely,Alison B. Durham, MD1Jennifer L. Schwartz, MD1Lori Lowe, MD1,2Lili Zhao, PhD3Andrew G. Johnson, BA4Kelly L. Harms MD, PhD1Christopher K. Bichakjian, MD1Amy P. Orsini, MD1Scott A. McLean, MD, PhD5Carol R. Bradford, MD5Mark S. Cohen, MD6Timothy M. Johnson, MD1,5,6Michael S. Sabel, MD6Sandra L. Wong MD, MS71Department of Dermatology, University of Michigan Hospital, Ann Arbor, Michigan2Department of Pathology, University of Michigan Health System, Ann Arbor, Michigan3Department of Biostatistics, University of Michigan Health System, Ann Arbor, Michigan4University of Michigan Medical School, Ann Arbor, Michigan5Department of Otolaryngology, University of Michigan Health System, Ann Arbor, Michigan6Surgery University of Michigan Medical School and Comprehensive Cancer Center, Ann Arbor, Michigan7Department of Surgery, Dartmouth‐Hitchcock Medical Center and Geisel School of Medicine at Dartmouth, Lebanon, New HampshireCorrespondenceAlison B. Durham, Department of Dermatology, University of Michigan Health System, 1500 E. Medical Center Dr, UH South F7672, Ann Arbor MI 48109‐5218.Email: ambates@med.umich.eduREFERENCESDurham AB, Schwartz JL, Lowe L, et al. The natural history of thin melanoma and the utility of sentinel lymph node biopsy. J Surg Oncol. 2017.Bax MJ, Johnson TM, Harms PW, et al. Detection of occult invasion in melanoma in situ. JAMA Dermatol. 2016;152:1201–1208. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Surgical Oncology Wiley

Loading next page...
1 Page
 
/lp/wiley/in-reply-management-of-thin-melanoma-SAq2NJWzNe
Publisher
Wiley Subscription Services, Inc., A Wiley Company
Copyright
© 2018 Wiley Periodicals, Inc.
ISSN
0022-4790
eISSN
1096-9098
D.O.I.
10.1002/jso.24858
Publisher site
See Article on Publisher Site

Abstract

Dear Editor,In the letter entitled “Management of thin melanoma,” Drs. Pusiol and Piscioli outline an algorithm for classification of melanoma into one of three types; nontumorigenic microinvasive radial growth phase (RGP) thin melanoma, tumorigenic early vertical growth phase (VGP) thin melanoma, or uncertain potentially tumorigenic thin melanoma. Further, the authors suggest that treatment decisions regarding performance of sentinel lymph node biopsy (SLNB) be based on this classification alone, with the recommendation that SLNB be performed for any VGP thin melanoma with a potential for regional nodal metastasis.The decision to perform SLNB has historically been based on the probability of finding a positive sentinel lymph node using independent prognostic variables of tumor and patient characteristics. In our study of 510 patients with 512 melanoma lesions Breslow thickness 0.75‐0.99 mm, univariate analysis showed age ≤45, Breslow depth ≥0.85 mm, mitotic rate>1/mm2, and ulceration to be significantly associated with nodal disease (either positive SLNB or nodal recurrence in the follow up period). To our knowledge, RGP and VGP have not been shown to be independent prognostic indicators of risk of nodal metastasis and, although the risk is low, it has been shown that very early thin lesions and even those interpreted as melanoma in situ can metastasize.Given that SLNB is a surgical test with associated risks, the recommendation to perform SLNB has been and should continue to be based on the probability (percentage) and not the possibility (yes/no) of regional lymph node disease. As such, we feel strongly that the decision to perform SLNB should be based upon a reasonable evaluation of the likelihood of potential benefit appropriately weighed against the surgical risk.CONFLICTS OF INTERESTNone.Sincerely,Alison B. Durham, MD1Jennifer L. Schwartz, MD1Lori Lowe, MD1,2Lili Zhao, PhD3Andrew G. Johnson, BA4Kelly L. Harms MD, PhD1Christopher K. Bichakjian, MD1Amy P. Orsini, MD1Scott A. McLean, MD, PhD5Carol R. Bradford, MD5Mark S. Cohen, MD6Timothy M. Johnson, MD1,5,6Michael S. Sabel, MD6Sandra L. Wong MD, MS71Department of Dermatology, University of Michigan Hospital, Ann Arbor, Michigan2Department of Pathology, University of Michigan Health System, Ann Arbor, Michigan3Department of Biostatistics, University of Michigan Health System, Ann Arbor, Michigan4University of Michigan Medical School, Ann Arbor, Michigan5Department of Otolaryngology, University of Michigan Health System, Ann Arbor, Michigan6Surgery University of Michigan Medical School and Comprehensive Cancer Center, Ann Arbor, Michigan7Department of Surgery, Dartmouth‐Hitchcock Medical Center and Geisel School of Medicine at Dartmouth, Lebanon, New HampshireCorrespondenceAlison B. Durham, Department of Dermatology, University of Michigan Health System, 1500 E. Medical Center Dr, UH South F7672, Ann Arbor MI 48109‐5218.Email: ambates@med.umich.eduREFERENCESDurham AB, Schwartz JL, Lowe L, et al. The natural history of thin melanoma and the utility of sentinel lymph node biopsy. J Surg Oncol. 2017.Bax MJ, Johnson TM, Harms PW, et al. Detection of occult invasion in melanoma in situ. JAMA Dermatol. 2016;152:1201–1208.

Journal

Journal of Surgical OncologyWiley

Published: Jan 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial